Morning Research on Arena Pharma, Incyte, Galena Biopharma, and Novavax

   Morning Research on Arena Pharma, Incyte, Galena Biopharma, and Novavax

PR Newswire

LONDON, March 19, 2013

LONDON, March 19, 2013 /PRNewswire/ --

One of the biggest trends to emerge in the healthcare industry in the last
year has been the expiration of patents on several blockbuster drugs. The
trend is expected to continue in 2013. The development has led to increasing
competition from generic drugs and has put pressure on major pharmaceutical
companies' top-line growth. As big pharma companies look to offset the loss of
revenue from patent expirations, one trend that can emerge is acquisition or
partnership with smaller biotechnology companies that are developing potential
blockbuster drugs. Among the biotechnology companies that could generate
interest among major pharmaceutical companies are Arena Pharmaceuticals Inc.
(NASDAQ: ARNA), Incyte Corporation (NASDAQ: INCY), Galena Biopharma Inc.
(NASDAQ: GALE), and Novavax Inc. (NASDAQ: NVAX). Biotechnology stocks ended on
a mixed note on Monday even as the broad market struggled. StockCall has
posted free technical research reports on ARNA, INCY, GALE, and NVAX and these
can be accessed by signing up at

Shares of biotechnology company Arena Pharmaceuticals Inc. fell sharply in
Monday's trading session, closing 1.87% lower at $7.88 on volume of 4.41
million. The stock has now fallen nearly 3% in the last three sessions, which
suggests that market sentiment is bearish on the stock. The stock has also
slipped below $8 support level, which further confirms the bearish trend. The
stock's MACD has also crossed below the signal line and is trading below the
zero-line. The 50-day moving average has crossed below the 200-day moving
average, forming a "death cross". Download the free report on ARNA upon
registration at 

Shares of Incyte Corporation were among the major losers yesterday. The stock
ended the day 4.23% lower at $23.79 on above average volume of 8.92 million.
Incyte's shares fell to an intra-day low of $21.79 before paring some of the
losses. Despite the sharp decline, the biotech company's shares have had an
excellent run so far in 2013, gaining more than 43%. The stock has seen a
pullback after failing to break through $25 resistance level. Volume activity
and the stock's MACD chart suggest that market sentiment has turned bearish on
Incyte Corp. INCY technical report can be accessed for free by signing up at 

Shares of Galena Biopharma Inc. rallied in Monday's trading session even as
the broad market struggled. The stock closed 5.21% higher at $2.02 on above
average volume of 2.18 million. Despite yesterday's rally, Galena's shares
have fallen more than 2.80% in the last three sessions. Year-to-date, however,
the stock has gained more than 32%, outperforming the broad market. Shares of
GALE are currently facing resistance at around $2.20. The stock has strong
support at around $1.90. The free report on GALE can be downloaded by signing
up now at 

Shares of Novavax Inc. rose sharply in trading its most recent session of
trading. The stock closed 1.43% higher at $2.13 on above average volume of
1.03 million. Novavax's shares have gained nearly 4% in the last three
sessions. The stock is currently trading close to its 52-week high of $2.44.
The company's shares have just broken through $2.10 resistance level, which is
a bullish signal. The upbeat trend is further confirmed by recent volume
activity and the stock's MACD chart. Free report on NVAX can be accessed by
registering at 

About is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at


Contact: William T. Knight, Email:, Contact Number:
+1-646-396-9857 (9:00 am EST - 01:30 pm EST)
Press spacebar to pause and continue. Press esc to stop.